TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospectiv...(ons rate implants infections rat...),Health

Date:5/14/2009

ons rate implants infections rate De novo 15 0 0.0% 51 0 0.0% Revision 38 0 0.0% 141 5 2.0% Total 53 0 0.0% 192 5 2.0% Other Total infection infection Implant Type implants infections rate implants infections rate De novo 1 0 0.0% 67 0 0.0% Revision 8 0 0.0% 187 5 2.0% Total 9 0 0.0% 254 5 2.0% All Patients w/ greater than or equal to 1 Follow-up & CRMD Infection designation restricted to Generator Pocket Infections Only PM ICD/CRT infection infection Implant Type implants infections rate implants infections rate De novo 15 0 0.0% 51 0 0.0% Revision 38 0 0.0% 141 3 1.2% Total 53 0 0.0% 192 3 1.2% Other Total infection infection Implant Type implants infections rate implants infections rate De novo 1 0 0.0% 67 0 0.0% Revision 8 0 0.0% 187 3 1.2% Total 9 0 0.0% 254 3 1.2% All Patients w/ greater than or equal to 1 Follow-up & CRMD Infection designation restricted to Generator Pocket Infections w/o CRMD infection in prior 6 mos.
'/>"/>

SOURCE TYRX, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens